Neisvac-C (Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated))

Neisvac-C is a combination vaccine that targets bacterial toxin and capsular polysaccharide disease pathways. It is indicated for:

• Tetanus: induces protective antibodies that neutralize tetanus toxin.
• Neisseria meningitidis group C infection: stimulates antibodies against the group C polysaccharide capsule to prevent invasive meningococcal disease.
• Travel to endemic regions: provides protection against group C meningococcal disease for travelers and pilgrims.

• Neisvac-C contains purified tetanus toxoid, an algeldrate adjuvant, and a de‑O‑acetylated polysaccharide from Neisseria meningitidis group C. The toxoid elicits a T‑cell‑dependent response that generates anti‑tetanus toxin antibodies, while the polysaccharide induces a B‑cell‑mediated response against the bacterial capsule. Algeldrate enhances antigen presentation, resulting in robust, long‑lasting humoral immunity against both pathogens.

Neisvac-C is generally well tolerated, but injection‑related reactions and rare systemic events have been reported.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness or swelling: localized erythema and edema.
• Fever: low‑grade temperature rise within 24‑48 hours.
• Headache: transient mild headache.
• Fatigue: temporary tiredness.
• Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare demyelinating neuropathy.
• Seizures: infrequent neurologic events.
• Severe hypotension: marked drop in blood pressure.
• Persistent high fever: prolonged temperature elevation.
• Severe local necrosis: extensive tissue damage at injection site.

Prior to administration, consider the following safety measures:

• Pregnancy: safety not established; vaccinate only if benefit outweighs risk.
• Breastfeeding: no known adverse effects, but consult a healthcare professional.
• Immunocompromised patients: vaccine may elicit reduced immune response.
• Known allergy: avoid if hypersensitivity to any vaccine component exists.
• Acute illness: postpone vaccination during moderate or severe febrile illness.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination may be influenced by concurrent therapies or other immunizations.

Major Interactions (Avoid)

• Live bacterial or viral vaccines: concurrent administration may interfere with immune response.
• Immunoglobulin therapy: can neutralize vaccine antigens and diminish effectiveness.

Moderate Interactions (Monitor Closely)

• Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may reduce antibody production.
• Antipyretics taken prophylactically: could mask early fever signals.
• Blood products administered within 48 hours: may lower vaccine efficacy.